Senseonics Holdings (SENS) Stock Forecast & Price Target

Senseonics Holdings is supported by a differentiated implantable CGM franchise that already reached commercial reality with Eversense 365, the first year-long CGM in the EU, while 1Q26 revenue of $11.7M grew 87% year over year and gross margin improved to 59%. Its outlook is further strengthened by the U.S. commercial transition, strong DTC-driven new patient adds, and the launch of the Eversense 365 combo with Sequel Med Tech’s twiist AID system, all of which can broaden adoption and expand use cases. Longer term, FREEDOM and Gemini could deepen the company’s moat by removing external hardware, with encouraging preclinical results, a planned pivotal study in 2027, and possible launches in 2027-2028 creating multiple innovation catalysts backed by $157M pro forma cash and expanded borrowing capacity.

Senseonics Holdings is a high-risk, structurally unprofitable medical technology company that has incurred significant operating losses since inception and still faces uncertainty about achieving sustained profitability, raising going-concern concerns if additional capital or better financial performance does not materialize. Its outlook is further weakened by heavy dependence on the exclusive Commercialization Agreement with Ascensia, meaning any underperformance in sales, marketing, or execution could sharply impair future revenue, commercialization, and growth. In a highly competitive and rapidly evolving diabetes monitoring market, the company’s limited commercial operating history and exposure to regulatory and clinical development delays increase the risk that Eversense could lose share or become less competitive.